HIMS - Hims & Hers Health, Inc.
Hims & Hers is a subscriber-based online healthcare provider that operates outside of the traditional paradigm. Its AI-native processes and visibility to each patient's full medical journey create a flywheel that's difficult for competitors to replicate. Its moat is further enhanced by its vertical integration and scale.
Hims & Hers Health is upgraded from "Hold" to "Buy," driven by operational discipline and strategic opportunism despite sector volatility. HIMS leverages FDA panel momentum on peptides, expanding into personalized treatments while maintaining a robust telehealth platform and global reach. Management pursues a "best in market" approach to peptide launches, prioritizing clinical rigor, validated supply chains, and data transparency over speed.
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health Inc. (NYSE:HIMS) is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four key peptides be added to a federal list that would allow compounding pharmacies to legally produce them.
Martin Shkreli is taking aim at Hims & Hers Health (NYSE:HIMS), saying he is short the stock and blasting the company's peptide products as illegitimate medicine
Hims & Hers Health is set to tap what analysts estimate could be a multi-billion-dollar market for peptides if U.S. regulators loosen manufacturing restrictions.
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.68, moving 3.21% from the previous trading session.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company after more than seven years, effective October 9, 2026. Becklund will then serve as an advisor to the company for several months to assist with the transition. The company will conduct a search for her permanent successor, with Yemi Okupe, CFO of Hims & Hers, assuming the responsibilities of.
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.15, moving +2.24% from the previous trading session.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, refe.
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
FDA staff challenged seven compounded peptides, but Hims & Hers continues expanding internationally and strengthening its core healthcare platform beyond longevity therapies. The $400 million JPMorgan receivables facility improves financial flexibility, supporting GLP-1 expansion without relying on dilutive equity financing. The $1.15 billion Eucalyptus acquisition adds 850,000 customers and approximately $450 million of ARR across eight international markets.
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $36.17, moving 5.51% from the previous trading session.
Hims & Hers Health continues to drive impressive growth through its subscription-based consumer wellness platform. Teladoc Health maintains a dominant market share with over 100 million global members and significant institutional partnerships.
The healthcare sector is one of the best-performing sectors in the S&P 500 over the past month, with a gain of around 6%. But while that rebound has been led by a handful of mega-cap Big Pharma companies, it has also been reflected in the performances of smaller firms.
The stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Monthly weight-loss subscriber additions exceed one hundred thousand, transforming GLP-1 products into a powerful customer acquisition funnel. Peptides, AI healthcare systems, and international expansion create multi-layered optionality beyond traditional telehealth and pharmacy models.
The Amplify Online Retail ETF (IBUY) has rallied over the past month, signaling a robust appetite for online consumer discretionary spending despite persistent macroeconomic headwinds. Outsized gains in specialized healthcare retail and online travel names have driven performance for IBUY's underlying index.
Hims & Hers Health shares (HIMS) surged 9% on Wednesday after Canaccord Genuity raised its price target on the telehealth company, citing improving sales trends, momentum in its weight-loss business, and growing optimism around its peptide opportunity. Canaccord analyst Maria Ripps maintained a Buy rating on the stock while increasing her price target to $40 from $32, implying additional upside from current levels.
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $33.39, indicating a -1.62% shift from the previous trading day.